Abstracts tagged "Interferons and systemic lupus erythematosus (SLE)"

Abstract Number: 2037 • 2019 ACR/ARP Annual Meeting
Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity
Theresa Lu ¹, Noa Schwartz ², Thomas Li ², William Shipman ³, Dragos Dasoveanu ³, Yong Liu ⁴, Niroshana Anandasabapathy ⁴, Henry Lee ⁴, Ali Jabbari ⁵, James Krueger ⁵, Bebak Mehrara ⁶, Keila Veiga², Kira Minkis ⁴ and David Oliver ², ¹Hospital for Special Surgery, Weill Cornell Medicine (Microbiology and Immunology), New York, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery; Weill Cornell Medicine, New York, ⁴Weill Cornell Medicine (Dermatology), New York, ⁵Rockefeller University, New York, ⁶Memorial Sloan Kettering Cancer Center, New York
Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus. Lesions can be disfiguring and have a negative impact on patients’ quality…
Abstract Number: 2572 • 2019 ACR/ARP Annual Meeting
Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status
Angela R Jones-Leone¹, Shaun Flint ², Roger Abramino Levy ³, David Roth ⁴, Robert Henderson ², Christel Wilkinson ², Beulah Ji ⁵ and Damon L Bass ³, ¹GlaxoSmithKline, Upper Providence, ²GlaxoSmithKline, Stevenage, United Kingdom, ³GlaxoSmithKline, Collegeville, PA, ⁴GSK, Collegeville, PA, ⁵GSK, Uxbridge, Middlesex, United Kingdom
Background/Purpose: Belimumab (BEL) is a B-lymphocyte stimulator (BLyS) inhibitor approved as an add-on to standard of care (SoC) for patients with autoantibody-positive SLE with active…
Abstract Number: 2685 • 2018 ACR/ARHP Annual Meeting
Interferon-Inducible Gene Expression Kit As a Potential Diagnostic Test for Anifrolumab: Analytical Validation for Use in Clinical Trials
Philip Z. Brohawn¹, Brandon W. Higgs¹, Sabina Patel², Adrian Moody³, Peter Cooper³ and Koustubh Ranade⁴, ¹MedImmune LLC, Gaithersburg, MD, ²AstraZeneca, Cambridge, United Kingdom, ³QIAGEN Manchester Ltd., Manchester, United Kingdom, ⁴Translational Medicine, MedImmune LLC, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human monoclonal antibody that binds to the type I interferon (IFN) receptor. Its efficacy and safety in the treatment of…
Abstract Number: 2951 • 2018 ACR/ARHP Annual Meeting
Ustekinumab Treatment Response in SLE Is Associated with Changes in Type II but Not Type I Interferons
Jarrat Jordan¹, Kristen Sweet², Matteo Cesaroni¹, Keying Ma², Carol Franks², Loqmane Seridi², Jessica Schreiter³, Robert Gordon², Peter E. Lipsky⁴, Shawn Rose², Frédéric Baribaud², Matthew Loza² and Kim Campbell², ¹Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: We previously reported that treatment with ustekinumab (UST), an anti-IL-12/23 p40 neutralizing monoclonal antibody, improved global and organ-specific measures of disease activity in a…
Abstract Number: 91 • 2018 ACR/ARHP Annual Meeting
Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE
Antonios Psarras^1,2,3, Adewonuola Alase¹, Agne Antanaviciute⁴, Ian Carr⁴, Miriam Wittmann^1,2, George C Tsokos⁵, Paul Emery^1,6 and Edward M Vital^1,2, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, ⁴Leeds Institute for Data Analytics, University of Leeds, Leeds, United Kingdom, ⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: SLE is characterized by persistently high type I IFN activity. Plasmacytoid dendritic cells (pDCs) produce large amounts of IFNs in viral infections in response…
Abstract Number: 917 • 2018 ACR/ARHP Annual Meeting
Type 1 Interferon Levels Correlates with Age of Diagnosis and Ethnicity in Systemic Lupus Erythematous
Majid Abedi¹, Lilian Borisov², Allison Doyle¹, Francisco Flores², June Fujimoto², Aviva Jacobs¹, Pramod Naranatt¹, Liuliu Pan², William Ricketts³, Jacob Spangler¹, Kristen Warren² and Robert Terbrueggen², ¹DxTerity, Rancho Domiquez, CA, ²DxTerity, Rancho Dominguez, CA, ³Clinical Operations, DxTerity, Rancho Domiquez, CA
Background/Purpose: Low cost, patient-administered, “from home” genomic tests for monitoring disease activity and therapy response could revolutionize treatment and management of Systemic Lupus Erythematous (SLE)…
Abstract Number: 1082 • 2018 ACR/ARHP Annual Meeting
Peripheral Blood CD11c+ CD21- Age-Associated B Cells (ABCs) in Human Systemic Lupus Erythematosus Are Associated with Innate Type III Interferon and Disease Activity
Jennifer L. Barnas, Lin Gao, Mary O'Connell, Jennifer Albrecht, Nida Meednu, R. John Looney and Jennifer Anolik, Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an interferon-stimulated gene (ISG) signature typically attributed to interferon (IFN)-α. However, ISGs can be induced by other…
Abstract Number: 1896 • 2018 ACR/ARHP Annual Meeting
Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling
Alex Tsoi¹, Grace Hile², Celine C. Berthier³, Mrinal Sarkar⁴, Tamra J. Reed⁵, Ranjitha Uppala⁴, Matthew Patrick⁴, Kalpana Raja⁴, Xianying Xing⁶, Kevin He², Johann Gudjonsson⁴ and Michelle Kahlenberg⁷, ¹Departments of Dermatology and Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Dermatology, University of Michigan, University of Michigan, Ann Arbor, MI, ⁷Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which 70% of patients experience disfiguring skin inflammation (grouped under the rubric of cutaneous…
Abstract Number: 4 • 2017 ACR/ARHP Annual Meeting
Downregulation of microRNAs in Plasmacytoid Dendritic Cells Is Associated with a Type I Interferon Signature in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Joel A.G. van Roon^2,3, Ruth D.E. Fritsch-Stork⁴, Cornelis P.J. Bekker¹, Aridaman Pandit¹, Marzia Rossato⁵ and Timothy R.D.J. Radstake¹, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Laboratory for Translational immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The most prominent alteration in the immune system of patients with SLE is a type I interferon (IFN) signature, which we recently also reported…
Abstract Number: 80 • 2017 ACR/ARHP Annual Meeting
Production and Characterization of Human Interferon-Epsilon and Interferon-Kappa to Investigate Their Potential Role in Lupus
Bethany D. Harris¹, Jessica Schreiter², Matteo Cesaroni³, Marc Chevrier³, Jarrat Jordan³, Jacqueline Benson³ and Mark R. Walter¹, ¹Microbiology, University of Alabama at Birmingham, Birmingham, AL, ²Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ³Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: IFNє and IFNκ are members of the type-I IFN family that also consists of 12 IFNα subtypes, IFNβ, and IFNω. IFNє and IFNκ share…
Abstract Number: 675 • 2017 ACR/ARHP Annual Meeting
Tissue-Based Biomarkers in Cutaneous Lupus Erythematosus: Type I IFN Responsive Protein Mxa and a Marker for Lymphocytic Inflammation (CD45) Correlate with CLASI Cross-Sectionally and Longitudinally
Taylor L. Reynolds¹, Carrie Wager¹, Stefan Hamann¹, Xueli Zhang¹, Galina Marsh¹, Cristina Musselli¹, Nathalie Franchimont¹, Agnes Gardet¹, Robert Dunstan², Dania Rabah¹ and Victoria P Werth³, ¹Biogen, Cambridge, MA, ²Abbvie, Worcester, MA, ³University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is the cutaneous manifestation of SLE, affecting 85% of patients1. CLE is subdivided into acute, subacute and chronic/discoid forms. Discoid…
Abstract Number: 831 • 2017 ACR/ARHP Annual Meeting
Interferon-Alpha Disrupts Tolerance in a Mouse Model of B Cell Anergy
Dario Ferri¹, Yuriy Baglaenko², Kieran Manion², Nan-Hua Chang² and Joan E. Wither³, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the production of anti-nuclear antibodies that deposit within tissues leading to organ damage. A central mediator of…
Abstract Number: 1014 • 2017 ACR/ARHP Annual Meeting
The Rheumatic Disease Data Refinery: A Case Study in Integrative Genomics Reveals Complex IFN Signatures in Therapeutic Studies in SLE
Jaclyn N Taroni and Casey S. Greene, Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Over the past 15 years, more than 10,000 whole tissue biopsies from patients with rheumatic diseases have been deposited into publicly available gene expression…
Abstract Number: 1842 • 2017 ACR/ARHP Annual Meeting
Subsetting Systemic Lupus Erythematosus By Interferon Gene Signatures and Serologies (anti-dsDNA and Low Complement) Uncovers Significant Clinical Diversity
Michelle Petri¹, Steven Watts², Richard Higgs², MaryAnn Morgan-Cox² and Matthew D Linnik³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: Personalized therapy in systemic lupus erythematosus (SLE) will require identifying SLE subsets that will benefit from different targeted therapies. Belimumab, for example, has…
Abstract Number: 1916 • 2017 ACR/ARHP Annual Meeting
The Interferon Gamma Release Assay Is a Novel Predictor of Disease Activity in Systemic Lupus Erythematosus
Jenna Thomason¹, Christian Lood² and Grant Hughes³, ¹Medicine, University of Washington, Seattle, WA, ²Division of Rheumatology, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Interferon gamma (IFN-G) is critical cytokine for defense against intracellular pathogens; it is also involved in the pathogenesis of systemic lupus erythematosus (SLE). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].